TFF, GreenLight partner on powder form mRNA vaccine formulation

By The Science Advisory Board staff writers

March 9, 2021 -- To address the cold storage challenge of messenger RNA (mRNA) vaccines, GreenLight Biosciences and TFF Pharmaceuticals have entered into a feasibility and material transfer agreement to evaluate a shelf-stable dry powder formulation of GreenLight's COVID-19 mRNA vaccine candidate.

Upon successful completion of the feasibility study, a further stage of work will include non-needle administration methods for the GreenLight mRNA vaccine candidate in a dry powder form that could be administered via a nasal spray or lung inhalation.

Under the agreement, GreenLight is delivering its COVID-19 mRNA product candidate materials to TFF with the goal of identifying an optimal formulation of the GreenLight mRNA product candidate in a dry powder form. Utilizing TFF's thin-film freezing platform, the companies will work to formulate a product that has superior stability, maintains particle size of the encapsulated mRNA as well as high encapsulation efficiency, and has rapid reconstitution characteristics for injection.

Copyright © 2021

MemberID or email address:  

Forgot your password?